| Budget Amount *help |
¥19,240,000 (Direct Cost: ¥14,800,000、Indirect Cost: ¥4,440,000)
Fiscal Year 2011: ¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2010: ¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2009: ¥10,270,000 (Direct Cost: ¥7,900,000、Indirect Cost: ¥2,370,000)
|
|---|
| Research Abstract |
The inhibitor of-apoptosis(IAP) family proteins are shown to be advantageous to cancer in many circumstances, including carcinogenesis, promotion, and therapy resistance. In this study, we focused on expression of anti-survivin, anti-livin and anti-XIAP antibodies as tumor markers in patients with colorectal polyp and cancer, and developed the screening array that can be automated. We compared positivity of anti-survivin, anti-livin, and anti-XIAP antibodies with existing tumor markers, including carcinoembryonic antigen(CEA), carbohydrate antigen 19-9(CA19-9), and anti-p53 antibody. So far, positivity of anti-livin antibody in patients with colorectal cancer was low at 2. 4%; positivity of CEA, CA19-9, and anti-p53 antibody were 39. 8%, 21. 6%, and 25. 0%, respectively. Positivity of anti-survivin and anti-XIAP antibodies was higher than other tumor markers at 37. 5% and 36. 3%, respectively. Furthermore, expression of anti-survivin and anti-XIAP antibodies was found not only in patients with early stage colorectal cancer but also in patients with colorectal polyps.
|
